Incidence of Autoimmune cytopenias after allogeneic HSCT for aplastic anaemia |
Study & Centre registration
| 4% |
Autoimmune conditions are a recognized complication following allogeneic haematopoietic stem cell transplant, and autoimmune cytopenias (AIC) are the most frequently encountered. AIC (autoimmune haemolytic anaemia, immune thrombocytopenia, Evan’s Syndrome and autoimmune neutropenia) developing post HSCT can pose a diagnostic challenge and may respond poorly to conventional therapy.
The aim of this joint study between the SAAWP, ADWP, C&QoLWP and PDWP is to estimate the incidence of AIC emerging as a complication following first allogeneic HSCT for severe aplastic anaemia (SAA). Further aims are to identify risk factors, and document diagnostic and treatment strategies, and response.
Inclusion criteria for this study are:
• Recipients of first allogeneic HSCT for idiopathic and secondary aplastic anaemia (but not including inherited bone marrow failure syndromes)
• Transplanted at your center between January 2002 and December 2012
Exclusion criterion for this study is:
• AIC diagnosed before diagnosis of AA or allograft
To assess the true incidence of AIC post allograft, we need to include as many patients as possible who fulfill the above criteria and not only patients developing AIC.
The aim of this joint study between the SAAWP, ADWP, C&QoLWP and PDWP is to estimate the incidence of AIC emerging as a complication following first allogeneic HSCT for severe aplastic anaemia (SAA). Further aims are to identify risk factors, and document diagnostic and treatment strategies, and response.
Inclusion criteria for this study are:
• Recipients of first allogeneic HSCT for idiopathic and secondary aplastic anaemia (but not including inherited bone marrow failure syndromes)
• Transplanted at your center between January 2002 and December 2012
Exclusion criterion for this study is:
• AIC diagnosed before diagnosis of AA or allograft
To assess the true incidence of AIC post allograft, we need to include as many patients as possible who fulfill the above criteria and not only patients developing AIC.